References
- Shattock SG. A new bone in human anatomy: together with an investigation into the morphological significance of the so-called internal lateral ligament of the human lower jaw. J. Anat. Physiol.14, 201–204 (1880).
- Anitschoff NN. Uber veranderungen der kaninchen-aorta bei experimentelle cholestrolinsteatose. Beitr. Path. Anat.56, 379–391 (1913).
- Anitschow N. On the morphodynamics of coronary sclerosis of the heart. Acta Pathol. Microbiol. Scand.49, 426–432 (1960).
- Hansson GK. Atherosclerosis – an immune disease: The Anitschkov Lecture 2007. Atherosclerosis202, 2–10 (2009).
- Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J.138, S419–S420 (1999).
- Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med.340, 115–126 (1999).
- Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation116, 1832–1844 (2007).
- Khalil MF, Wagner WD, Goldberg IJ. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler. Thromb. Vasc. Biol.24, 2211–2218 (2004).
- Chait A, Wight TN. Interaction of native and modified low-density lipoproteins with extracellular matrix. Curr. Opin. Lipidol.11, 457–463 (2000).
- Williams KJ. Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis, Curr. Opin. Lipidol.12, 477–487 (2001).
- Palinski W, Rosenfeld ME, Yla-Herttuala S et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl Acad. Sci. USA86, 1372–1376 (1989).
- Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc. Natl Acad. Sci. USA87, 904–908 (1990).
- Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler. Thromb.12, 461–467 (1992).
- Libby P. Inflammation in atherosclerosis. Nature420, 868–874 (2002).
- Febbraio M, Podrez EA, Smith JD et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest.105, 1049–1056 (2000).
- Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J. Clin. Invest.119, 136–145 (2009).
- Cao C, Lawrence DA, Strickland DK, Zhang L. A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood106, 3234–3241 (2005).
- Podrez EA, Febbraio M, Sheibani N et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest.105, 1095–1108 (2000).
- Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol. Cell. Biol.15, 954–963 (1995).
- Yu DH, Qu CK, Henegariu O, Lu X, Feng GS. Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J. Biol. Chem.273, 21125–21131 (1998).
- Wu RF, Terada LS. Oxidative modification of protein tyrosine phosphatases. Sci STKE332, pl2 (2006).
- Curtiss LK. Reversing atherosclerosis? N. Engl. J. Med.360, 1144–1146 (2009).
- Jensen LO, Thayssen P, Pedersen KE, Stender S, Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation110, 265–270 (2004).
- Okazaki S, Yokoyama T, Miyauchi K et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation110, 1061–1068 (2004).
- Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295, 1556–1565 (2006).
- Sirtori CR, Calabresi L, Marchioli R, Rubins HB. Cardiovascular risk changes after lipid lowering medications: are they predictable? Atherosclerosis152, 1–8 (2000).
- Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med.354, 1264–1272 (2006).
- Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials? Am. J. Cardiol.98, P18–P25 (2006).